Hematologic malignancies

Current Opinion in Hematology

Volumn 8, Issue 4, 2001, Pages 189-191

  Gilliland, D Gary ^a,b,c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORE BINDING FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; RETINOIC ACID RECEPTOR; STAT PROTEIN; TRANSCRIPTION FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; CHROMOSOME 20Q; CHROMOSOME 5Q; CHROMOSOME 7Q; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; GENE MUTATION; GENE REARRANGEMENT; GENETIC HETEROGENEITY; HUMAN; LEUKEMIA; LEUKEMOGENESIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SHORT SURVEY;

ACUTE DISEASE; DISEASE PROGRESSION; HUMANS; LEUKEMIA, MYELOID; MODELS, GENETIC; MUTATION; TRANSLOCATION, GENETIC;

EID: 0034890863     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200107000-00001     Document Type: Short Survey

References (1)

1. Efficacy and safety of a specific inhibitor of the BCR/ABL tyrosine kinase in chronic myeloid leukemia